Logo

BMS's Reblozyl (luspatercept) Receives Health Canada Approval for Beta Thalassemia

Share this

BMS's Reblozyl (luspatercept) Receives Health Canada Approval for Beta Thalassemia

Shots:  

  • The approval is based on the P-lll BELIEVE study assessing Reblozyl (luspatercept) + BSC vs PBO + BSC in adult patients with anemia associated with beta-thalassemia requiring regular RBC transfusions
  • Result: ≥33% reduction in RBC transfusion with a reduction of ≥2units from 13-24wks. (21.4% vs. 4.5%)- results were published in NEJM
  • Reblozyl regulate late-stage RBC maturation to potentially reduce the number of regular RBC transfusions and is the first and only erythroid maturation agent approved in Canada

­ Ref: BMS | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions